Indications/Uses
Hereditary angioedema.
|
Dosage/Direction for Use
Adult : SC Patient w/ C1-esterase inhibitor deficiency: 30 mg as a single dose during acute attack. May repeat dose 6 hrly if response is inadequate or symptoms recur. Max: 90 mg/day.
|
Dosage Details
Subcutaneous
Hereditary angioedema Adult: Patient w/ C1-esterase inhibitor deficiency: 30 mg as a single dose during acute attack. May repeat dose 6 hrly if response is inadequate or symptoms recur. Max: 90 mg daily.
|
Special Precautions
Patient w/ acute ischaemic heart disease, unstable angina pectoris, history or recently had a stroke.
|
Adverse Reactions
Significant: Airway obstruction.
Nervous: Dizziness, headache. GI: Nausea. Hepatic: Increased serum transaminase. Dermatologic: Rash, erythema, pruritus. Others: Pyrexia, inj site reaction (e.g. burning, swelling, itching, warm sensation, pain). |
Patient Counseling Information
This drug may cause dizziness, if affected, do not drive or operate machinery.
|
MonitoringParameters
Monitor symptom relief; laryngeal symptoms or airway obstruction.
|
Drug Interactions
Decreased antihypertensive effect of ACE inhibitors.
|
Action
Description: Icatibant, a selective bradykinin antagonist, inhibits bradykinin from binding B2 receptor which causes vasodilation, localised swelling, inflammation and acute pain and thereby relieves the symptoms of acute attack.
Onset: 50% decrease in symptoms: Approx 2 hr. Duration: Approx 6 hr. Pharmacokinetics: Absorption: Bioavailability: Approx 97%. Time to peak plasma concentration: 0.75 hr. Distribution: Volume of distribution: 20-25 L. Plasma protein binding: 44%. Metabolism: Extensively metabolised by proteolytic enzymes to inactive metabolites. Excretion: Mainly via urine, <10% as unchanged drug. Elimination half-life 1-1.8 hr. |
Chemical Structure
![]() Source: National Center for Biotechnology Information. PubChem Database. Icatibant, CID=6918173, https://pubchem.ncbi.nlm.nih.gov/compound/6918173 (accessed on Jan. 21, 2020) |
Storage
Store between 2-25°C. Follow applicable procedures for receiving, handling, admin, and disposal. Wear gloves during receiving, unpacking, and placing in storage.
|
MIMS Class
|
ATC Classification
B06AC02 - icatibant ; Belong to the class of drugs used in the treatment of hereditary angioedema.
|
References
Anon. Icatibant. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/12/2017. Buckingham R (ed). Icatibant Acetate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/12/2017. Firazyr Injection, Solution (Shire US Manufacturing Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/12/2017. Joint Formulary Committee. Icatibant. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/12/2017. McEvoy GK, Snow EK, Miller J et al (eds). Icatibant Acetate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 05/12/2017.
|